A new 137-foot, eight-story life science building is moving forward in the heart of the city’s Bayfront area, as the South San Francisco Planning Commission approved the project’s California Environmental Quality Act and design review requirements on Thursday, Oct. 19. 

The 573 Forbes Blvd. property was purchased by Vigilant Holdings and SmartLabs — the former of which acquired another South San Francisco property at Eccles Avenue last year — and will add to the city’s existing life science hub, which includes Genentech, AstraZeneca, AbbVie and Amgen. 

Recommended for you

alyse@smdailyjournal.com

(650) 344-5200 ext. 102

Recommended for you

(0) comments

Welcome to the discussion.

Keep the discussion civilized. Absolutely NO personal attacks or insults directed toward writers, nor others who make comments.
Keep it clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't threaten. Threats of harming another person will not be tolerated.
Be truthful. Don't knowingly lie about anyone or anything.
Be proactive. Use the 'Report' link on each comment to let us know of abusive posts.
PLEASE TURN OFF YOUR CAPS LOCK.
Anyone violating these rules will be issued a warning. After the warning, comment privileges can be revoked.

Thank you for visiting the Daily Journal.

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account.

We offer one free story view per month. If you register for an account, you will get two additional story views. After those three total views, we ask that you support us with a subscription.

A subscription to our digital content is so much more than just access to our valuable content. It means you’re helping to support a local community institution that has, from its very start, supported the betterment of our society. Thank you very much!

Want to join the discussion?

Only subscribers can view and post comments on articles.

Already a subscriber? Login Here